Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Molecular Assay Used to Diagnose Buruli Ulcer.

By LabMedica International staff writers
Posted on 29 Oct 2012
A simple diagnostic test for the causative agent of Buruli Ulcer has been reported, which could be used at point of care facilities, in resource-poor settings.

The quick and inexpensive diagnostic test can identify Mycobacterium ulcerans, the bacterium responsible for Buruli Ulcer (BU), and could replace the current laboratory diagnosis based on microscopy, which has to be confirmed by polymerase chain reaction (PCR) and other tests in reference laboratories.

Scientists at the Noguchi Memorial Institute for Medical Research (Accra, Ghana) employed the methodology based on the loop mediated isothermal amplification (LAMP) technique. More...
Four sets of Primers, targeting the mycolactone encoding plasmid genome sequence of M. ulcerans were designed. The BU-LAMP assay was developed and tested on five M. ulcerans strains from patients in Ghana and two reference isolates. The BU-LAMP assay protocol was optimized for maximum efficiency, using the Loopamp DNA amplification kit (Eiken Chemical; Tokyo, Japan).

The assay was tested on other closely related, mycolactone-producing mycobacterial strains; M. marinum, M. liflandii and M. pseudoshotsii, as well as experimentally infected laboratory animal and clinical samples. The results revealed a high specificity of the BU-LAMP assay for selectively detecting M. ulcerans. Compared to the conventional PCR, the new assay is cheaper, simpler, and ten times more sensitive. The test results can be obtained within one hour. The DNA concentration at the visual detection limit was estimated to be 48 pg/μL. However, by measuring the optical density (OD) value of BU-LAMP products at 350 and 450 nm, the scientists were able to detect positivity when using DNA concentrations as low as 0.5 fg/μL.

The authors concluded that the BU-LAMP method shows promise as a diagnostic tool at point of care facilities in BU endemic communities. Unlike the conventional PCR method that requires the use of a thermal cycler, purified DNA samples are not a requirement. DNA amplification occurs within one hour and the resulting product is a turbid solution, indicative of product amplification. Sample confirmation can therefore be done visually with the naked eye, and the intensity of the fluorescence observed is indicative of amount of DNA present. The study was first published online on January 12, 2012, in the journal BMC Infectious Diseases.

Related Links:

Noguchi Memorial Institute for Medical Research
Eiken Chemical



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.